Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-mi-2 autoantibodies

Yoshinao Muro, Asuka Ishikawa, Kazumitsu Sugiura, Masashi Akiyama

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective. Myositis-specific autoantibodies (MSAs), which characterize certain forms of inflammatory myopathy, are useful in the diagnosis and prediction of prognosis in DM/PM. Anti-transcriptional intermediary factor 1-α (TIF1-α) antibodies were recently reported to be associated with cancer-associated DM in conjunction with anti-TIF1-γ antibodies. This study aimed to identify a subset of DM patients who have anti-TIF1-α antibodies by using biotinylated recombinant proteins and to clarify the clinical and other serological features of DM patients with these antibodies.Methods. Sera from 202 Japanese patients with CTDs, including 108 with DM and 20 healthy controls, were screened for anti-TIF1-α antibodies by our novel ELISAs. Positive sera were further examined by immunoprecipitation and also investigated for the detection of anti-TIF1-γ and anti-Mi-2 antibodies.Results. Sera from 12 patients with DM were confirmed to be positive for anti-TIF1-α antibodies. None of the patients with other CTDs and none of the healthy controls had the antibodies. Seven anti-TIF1-α-positive patients simultaneously had anti-TIF1-γ antibodies and the other five had anti-Mi-2 antibodies, both of which are well known to be MSAs. These double-positive patients with anti-TIF1-α and anti-γ antibodies included three JDM and two cancer-associated adult DM patients, whereas all the double-positive patients with anti-TIF1-α and anti-Mi-2 antibodies were classical adult DM.Conclusion. Although MSAs have been regarded as mutually exclusive, anti-Mi-2 antibody-positive patients simultaneously have anti-TIF1-α antibodies. Anti-Mi-2 antibody-positive patients are associated with classical DM without cancer even with the simultaneous presence of anti-TIF1-α antibodies.

Original languageEnglish
Article numberkes073
Pages (from-to)1508-1513
Number of pages6
JournalRheumatology (United Kingdom)
Volume51
Issue number8
DOIs
Publication statusPublished - 01-08-2012

Fingerprint

Dermatomyositis
Autoantibodies
Antibodies
Myositis
Mi-2 antibodies
transcriptional intermediary factor 1
Serum
Neoplasms
Immunoprecipitation
Recombinant Proteins
Anti-Idiotypic Antibodies
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

Cite this

@article{e0fe700a7ac74212869f01761ad116f4,
title = "Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-mi-2 autoantibodies",
abstract = "Objective. Myositis-specific autoantibodies (MSAs), which characterize certain forms of inflammatory myopathy, are useful in the diagnosis and prediction of prognosis in DM/PM. Anti-transcriptional intermediary factor 1-α (TIF1-α) antibodies were recently reported to be associated with cancer-associated DM in conjunction with anti-TIF1-γ antibodies. This study aimed to identify a subset of DM patients who have anti-TIF1-α antibodies by using biotinylated recombinant proteins and to clarify the clinical and other serological features of DM patients with these antibodies.Methods. Sera from 202 Japanese patients with CTDs, including 108 with DM and 20 healthy controls, were screened for anti-TIF1-α antibodies by our novel ELISAs. Positive sera were further examined by immunoprecipitation and also investigated for the detection of anti-TIF1-γ and anti-Mi-2 antibodies.Results. Sera from 12 patients with DM were confirmed to be positive for anti-TIF1-α antibodies. None of the patients with other CTDs and none of the healthy controls had the antibodies. Seven anti-TIF1-α-positive patients simultaneously had anti-TIF1-γ antibodies and the other five had anti-Mi-2 antibodies, both of which are well known to be MSAs. These double-positive patients with anti-TIF1-α and anti-γ antibodies included three JDM and two cancer-associated adult DM patients, whereas all the double-positive patients with anti-TIF1-α and anti-Mi-2 antibodies were classical adult DM.Conclusion. Although MSAs have been regarded as mutually exclusive, anti-Mi-2 antibody-positive patients simultaneously have anti-TIF1-α antibodies. Anti-Mi-2 antibody-positive patients are associated with classical DM without cancer even with the simultaneous presence of anti-TIF1-α antibodies.",
author = "Yoshinao Muro and Asuka Ishikawa and Kazumitsu Sugiura and Masashi Akiyama",
year = "2012",
month = "8",
day = "1",
doi = "10.1093/rheumatology/kes073",
language = "English",
volume = "51",
pages = "1508--1513",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-mi-2 autoantibodies

AU - Muro, Yoshinao

AU - Ishikawa, Asuka

AU - Sugiura, Kazumitsu

AU - Akiyama, Masashi

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Objective. Myositis-specific autoantibodies (MSAs), which characterize certain forms of inflammatory myopathy, are useful in the diagnosis and prediction of prognosis in DM/PM. Anti-transcriptional intermediary factor 1-α (TIF1-α) antibodies were recently reported to be associated with cancer-associated DM in conjunction with anti-TIF1-γ antibodies. This study aimed to identify a subset of DM patients who have anti-TIF1-α antibodies by using biotinylated recombinant proteins and to clarify the clinical and other serological features of DM patients with these antibodies.Methods. Sera from 202 Japanese patients with CTDs, including 108 with DM and 20 healthy controls, were screened for anti-TIF1-α antibodies by our novel ELISAs. Positive sera were further examined by immunoprecipitation and also investigated for the detection of anti-TIF1-γ and anti-Mi-2 antibodies.Results. Sera from 12 patients with DM were confirmed to be positive for anti-TIF1-α antibodies. None of the patients with other CTDs and none of the healthy controls had the antibodies. Seven anti-TIF1-α-positive patients simultaneously had anti-TIF1-γ antibodies and the other five had anti-Mi-2 antibodies, both of which are well known to be MSAs. These double-positive patients with anti-TIF1-α and anti-γ antibodies included three JDM and two cancer-associated adult DM patients, whereas all the double-positive patients with anti-TIF1-α and anti-Mi-2 antibodies were classical adult DM.Conclusion. Although MSAs have been regarded as mutually exclusive, anti-Mi-2 antibody-positive patients simultaneously have anti-TIF1-α antibodies. Anti-Mi-2 antibody-positive patients are associated with classical DM without cancer even with the simultaneous presence of anti-TIF1-α antibodies.

AB - Objective. Myositis-specific autoantibodies (MSAs), which characterize certain forms of inflammatory myopathy, are useful in the diagnosis and prediction of prognosis in DM/PM. Anti-transcriptional intermediary factor 1-α (TIF1-α) antibodies were recently reported to be associated with cancer-associated DM in conjunction with anti-TIF1-γ antibodies. This study aimed to identify a subset of DM patients who have anti-TIF1-α antibodies by using biotinylated recombinant proteins and to clarify the clinical and other serological features of DM patients with these antibodies.Methods. Sera from 202 Japanese patients with CTDs, including 108 with DM and 20 healthy controls, were screened for anti-TIF1-α antibodies by our novel ELISAs. Positive sera were further examined by immunoprecipitation and also investigated for the detection of anti-TIF1-γ and anti-Mi-2 antibodies.Results. Sera from 12 patients with DM were confirmed to be positive for anti-TIF1-α antibodies. None of the patients with other CTDs and none of the healthy controls had the antibodies. Seven anti-TIF1-α-positive patients simultaneously had anti-TIF1-γ antibodies and the other five had anti-Mi-2 antibodies, both of which are well known to be MSAs. These double-positive patients with anti-TIF1-α and anti-γ antibodies included three JDM and two cancer-associated adult DM patients, whereas all the double-positive patients with anti-TIF1-α and anti-Mi-2 antibodies were classical adult DM.Conclusion. Although MSAs have been regarded as mutually exclusive, anti-Mi-2 antibody-positive patients simultaneously have anti-TIF1-α antibodies. Anti-Mi-2 antibody-positive patients are associated with classical DM without cancer even with the simultaneous presence of anti-TIF1-α antibodies.

UR - http://www.scopus.com/inward/record.url?scp=84865192477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865192477&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kes073

DO - 10.1093/rheumatology/kes073

M3 - Article

C2 - 22539482

AN - SCOPUS:84865192477

VL - 51

SP - 1508

EP - 1513

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 8

M1 - kes073

ER -